Sight Sciences operates as a growth-stage medical device enterprise that is currently unprofitable on a net income basis, continuing to post periodic net losses as it invests heavily in commercial scaling, research, and market development. However, the company demonstrates exceptionally high gross margins exceeding 90% and has successfully narrowed its quarterly operating losses through disciplined expense management, steadily advancing toward its long-term financial breakeven goals.